glp 1 obesity treatment What's New in Treatment? GLP-1 Agonists For Obesity In

SGLT2 inhibitors cause a carbohydrate deficit by glucosuria, which leads to an increased glucagon/insulin ratio, the metabolic shift from glucose to lipid utilization causing ketogenesis, and hence euglycemic DKA

Disclosure: I hold a bullish position in Altimmune (ALT) through call options expiring January 2027 a leveraged, directional position that profits if the stock rises

| SP Nutra is a biosciences company focused on the science of food and plants, discovering and developing powerful bioactives into consumer products that target the global metabolic health crisis

Today, we announced our investigational glucagon/GLP-1 dual receptor agonist achieved key measures of success at 48 weeks in our IMPACT Phase 2b trial and recent interactions with the FDA have resulted in alignment on the parameters for a registrational Phase 3 trial

In addition, Dula decreased the oxidative stress biomarker malondialdehyde (MDA) and increased the antioxidant enzymes (total antioxidant capacity (TAC), reduced glutathione (GSH), and superoxide dismutase (SOD) concentrations)

Over two percent of adult patients now take a GLP-1 drug to treat overweight or obesity, according to a FAIR Health white paper entitled, Obesity and GLP-1 Drugs: A Claims-Based Analysis